Talphera Inc. (TLPH)
Summary
Talphera, Inc. (TLPH) Q1 2026 Earnings Call Transcript
Talphera, Inc. (TLPH) Q1 2026 Earnings Call Transcript
Talphera, Inc. (TLPH) Analyst/Investor Day Transcript
Talphera, Inc. (TLPH) Analyst/Investor Day Transcript
Talphera, Inc. (TLPH) Q3 2025 Earnings Call Transcript
Talphera, Inc. ( TLPH ) Q3 2025 Earnings Call November 12, 2025 4:30 PM EST Company Participants Raffi Asadorian - Chief Financial Officer Vincent Angotti - CEO & Director Shakil Aslam - Chief Medical Officer Conference Call Participants Nazibur Rahman - Maxim Group LLC, Research Division Presentation Operator Welcome to the Talphera Third Quarter 2025 Financial Results Conference Call. This call is being webcast live via the Events page of the Investors section of Talphera's website at www.Talphera.com.
Talphera Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| EW Ed West Values First Advisors Inc. | 81,208 | $83,701.81 | $66,590.56 | -$17,111.25 | -20.44% |
| MO Matthew Okkerse Dauntless Investment Group LLC | 435,234 | $496,166.89 | $361,244.22 | -$134,922.67 | -27.19% |
| YML Yuen Man Lee Persistent Asset Partners Ltd. | 36,630 | $41,758 | $30,036.6 | -$11,721.4 | -28.07% |
| DWM Dogwood Wealth Management LLC Dogwood Wealth Management LLC | 10 | $5 | $8.2 | $3.2 | 64% |
Talphera Inc. (TLPH) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Talphera Inc. ever had a stock split?
Talphera Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Vincent J. Angotti CEO | NASDAQ (CM) Exchange | 00444T209 CUSIP |
| US Country | 13 Employees | - Last Dividend | 26 Oct 2022 Last Split | - IPO Date |
Overview
Talphera, Inc. is a forward-thinking specialty pharmaceutical company with a sharp focus on pioneering and commercializing therapeutic solutions intended for use within medically supervised environments. Initially known as AcelRx Pharmaceuticals, Inc., the organization transitioned to its current identity in January 2024, marking a new chapter in its journey towards innovation in healthcare. Founded in 2005 and with its headquarters nestled in San Mateo, California, Talphera, Inc. is dedicated to addressing a range of medical conditions through its robust pipeline of product candidates.
Products and Services
Niyad: Positioned as Talphera, Inc.'s flagship product candidate, Niyad is a lyophilized formulation of nafamostat. It currently operates under an investigational device exemption, showcasing its promise as a revolutionary anticoagulant specifically designed for use within extracorporeal circuits. This innovation highlights Talphera's commitment to transforming the landscape of medical care in highly specialized settings.
LTX-608: At the cutting edge of Talphera's ambitious project pipeline lies LTX-608. This compound is being explored for its dual anti-inflammatory and antiviral capabilities, with the aim of treating a spectrum of conditions. Among its potential applications are the treatment of COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis, showcasing the vast reach of Talphera's research and development efforts.
Fedsyra: Further expanding its diverse portfolio, Talphera, Inc. introduces Fedsyra, a uniquely pre-filled ephrine syringe designed for precision and ease of use in critical care settings. This development reflects the company’s dedication to addressing the nuanced demands of medical practitioners and patients alike.
PFS-02: Complementing its lineup of innovative healthcare solutions, PFS-02, a pre-filled phenylephrine syringe, stands as a testament to Talphera, Inc.'s commitment to pioneering convenient and reliable options for healthcare providers. This product underscores the company's holistic approach to healthcare innovation, catering to a wide array of medical needs and operational efficiencies.
